Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Massachusetts

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Legal Recourse

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical risks and therapeutic benefits. This legacy context has traditionally emphasized broad awareness of disease prevention, treatment protocols, and the importance of informed patient consent. Within this framework, the discussion of pharmaceutical interventions has focused on balancing efficacy against known adverse effects, often framed in population-level statistics and clinical guidelines. As we pivot from this general health perspective toward a more specific occupational exposure concern, the focus narrows to the real-world implications of drug-related risks in professional settings. The case of Tysabri, a medication used for certain chronic conditions, and its association with Progressive Multifocal Leukoencephalopathy (PML) illustrates this transition. While general health discourse might address PML as a rare complication, the occupational lens shifts attention to the legal and procedural dimensions that arise when such risks materialize. In Massachusetts, the statute of limitations for claims related to Tysabri exposure and subsequent PML development becomes a critical consideration for affected individuals navigating the settlement process. This pivot moves from abstract health education to the concrete, time-sensitive realities of liability and recourse, where the legacy of general health information now serves as a backdrop for understanding the stakes involved in occupational or therapeutic exposure scenarios.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Massachusetts who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits for filing a claim is critical. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and physicians must weigh expected benefits against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in immunocompromised patients and leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation may include progressive neurological deficits such as weakness, visual changes, cognitive decline, or coordination problems. Diagnosis relies on MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported even after Tysabri discontinuation in patients without suggestive findings at the time of stopping; monitoring should continue for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of PML and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect in the brain allows JC virus reactivation and uncontrolled replication, leading to demyelinating lesions characteristic of PML. The risk is highest in patients who are anti-JCV antibody positive, have received more than two years of therapy, or have prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients in Massachusetts who have developed PML after Tysabri treatment, settlement considerations involve the adequacy of warnings provided by the manufacturer. The boxed warning clearly states the PML risk and identifies risk factors, but questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, especially for those with multiple risk factors. The timeline between Tysabri exposure and documented harm is critical: PML typically develops after months to years of treatment, with risk increasing beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have occurred after discontinuation, complicating the determination of when the injury occurred for statute of limitations purposes.

Massachusetts Statute of Limitations for Tysabri PML Claims

Massachusetts law generally requires that a medical malpractice or product liability claim be filed within three years of the date the injury was discovered or should have been discovered. For PML, the date of discovery may be the date of diagnosis via MRI and CSF analysis. Given that PML can progress rapidly and lead to severe disability or death, early diagnosis is essential but often delayed due to nonspecific initial symptoms. The statute of limitations may also be affected by the patient's cognitive capacity after PML, as the disease often impairs decision-making. In such cases, tolling provisions may apply, but these are fact-specific and require legal evaluation. In summary, Tysabri-associated PML is a severe, often fatal condition with well-defined risk factors and a clear mechanistic basis. Patients in Massachusetts who have suffered this harm should be aware of the three-year statute of limitations from discovery of the injury. The adequacy of warnings, the duration of therapy, and the presence of anti-JCV antibodies are key factors in both medical management and potential settlement considerations. Legal counsel with experience in pharmaceutical litigation should be consulted promptly to preserve claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Massachusetts?

Massachusetts law generally requires that a medical malpractice or product liability claim be filed within three years from the date the injury was discovered or should have been discovered. For PML, this is typically the date of diagnosis via MRI and CSF analysis. However, due to the progressive nature of PML and potential cognitive impairment, tolling provisions may apply. It is crucial to consult an attorney promptly to preserve your claim.

What are the key risk factors for developing PML from Tysabri?

The three main risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are identified in the FDA-approved prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients with multiple risk factors have a higher likelihood of developing PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.